Chimeric Therapeutics Limited

NK Cell Derived Allogeneic Therapies

Team

About Cell Therapy

Pipeline

T Cell Derived Autologous Therapies

Science

Updates

New investors

Governance

Announcements

Investor Hub

Home

About Us

DM Sans

Click here to visit our dedicated Entitlement Offer (NREO) page for all the information you need to participate. 

Natural killer cells are part of our innate immune system providing direct and indirect mechanisms for killing cancer and an ideal foundation for off the shelf (allogeneic) cell therapy development.

NATURAL DETECTION AND DIRECT KILLING OF CANCER CELLS

Natural killer cells patrol our bodies looking for abnormal cells. They have an innate ability to recognize and and kill cancer cells without any priming or prior activation. (They’re named for this “natural” killing ability).

Natural killer cells are also able to produce cytokines that recruit and activate the immune system to mount an additional response to kill cancer cells.

NATURAL KILLER CELLS ALSO PROVIDE AN IDEAL UNIVERSAL PLATFORM FOR ALLOGENEIC (OFF THE SHELF) DEVELOPMENT.

Natural killer cells have fail-safe mechanisms that prevent the killing of healthy cells making them ideal for off the shelf platforms.

The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products.

Natural killer cells are found in our bodies naturally and are able to recognise and kill cancer cells – but are not robust and active enough to overcome cancer as it grows

CORE-NK platform cells are made by activating and expanding natural killer cells to make them more active and robust

CORE-NK platform cells have been studied in a phase 1 clinical trial in blood cancers and solid tumours

The next generation CORE-NK platform will integrate additional activation and expansion features to further optimise the cancer-fighting power of the CORE-NK platform cells.
Development of the next generation CORE-NK platform will be as a combination therapy for blood cancers.

CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen Receptor.

CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen Receptor.

CHM 3301 (Undisclosed CAR NK) will be developed on the next generation CORE-NK platform leveraging a currently undisclosed Chimeric Antigen Receptor.